Delta-Fly Pharma, Inc. (4598.T)
JPY 456.0
(0.0%)
JPY 456.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.4 Billion JPY | -6.68% |
| 2022 | -1.32 Billion JPY | -36.92% |
| 2021 | -960 Million JPY | -11.95% |
| 2020 | -857.32 Million JPY | 44.47% |
| 2019 | -1.55 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -496.75 Thousand JPY | 4.8% |
| 2023 FY | - JPY | -6.68% |
| 2023 Q1 | -275.57 Million JPY | 4.79% |
| 2023 Q4 | -454.07 Million JPY | -27.57% |
| 2023 Q3 | -355.94 Million JPY | -11.98% |
| 2023 Q2 | -317.87 Million JPY | -15.35% |
| 2022 Q3 | -414.75 Million JPY | -35.12% |
| 2022 Q4 | -289.44 Million JPY | 30.21% |
| 2022 FY | - JPY | -36.92% |
| 2022 Q2 | -306.95 Million JPY | 0.0% |
| 2021 FY | - JPY | -11.95% |
| 2020 FY | - JPY | 44.47% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 246.331% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -187.217% |
| GNI Group Ltd. | 14.48 Billion JPY | 109.676% |
| Linical Co., Ltd. | 1.24 Billion JPY | 212.409% |
| Trans Genic Inc. | 240.95 Million JPY | 681.859% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | -3.403% |
| Soiken Holdings Inc. | -583.2 Million JPY | -140.395% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -132.469% |
| AnGes, Inc. | -8.86 Billion JPY | 84.176% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | -9.063% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 81.051% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 1194.398% |
| NanoCarrier Co., Ltd. | -863 Million JPY | -62.457% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | -28.414% |
| CanBas Co., Ltd. | 53.65 Million JPY | 2713.185% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | -80.765% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -1154.014% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | -15.702% |
| Kidswell Bio Corporation | -1.38 Billion JPY | -1.534% |
| PeptiDream Inc. | 7.37 Billion JPY | 119.007% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 27.346% |
| Ribomic Inc. | -1.01 Billion JPY | -38.466% |
| SanBio Company Limited | -4.52 Billion JPY | 69.017% |
| Healios K.K. | -3 Billion JPY | 53.375% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | -20.262% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | -0.641% |
| StemRIM | -2.03 Billion JPY | 31.004% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 207.315% |
| FunPep Company Limited | -952 Million JPY | -47.269% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -57.748% |
| Stella Pharma Corporation | -723.85 Million JPY | -93.685% |
| TMS Co., Ltd. | -937 Million JPY | -49.626% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -80.812% |
| Cuorips Inc. | -518 Million JPY | -170.656% |
| K Pharma,Inc. | 366.05 Million JPY | 482.999% |
| Takara Bio Inc. | 8.02 Billion JPY | 117.473% |
| ReproCELL Incorporated | 8.24 Million JPY | 17104.245% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 1694.305% |
| StemCell Institute Inc. | 534.35 Million JPY | 362.373% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 672.68% |
| CellSeed Inc. | -836.51 Million JPY | -67.6% |